Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Interest & Investment Income (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Interest & Investment Income for 4 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income rose 12.72% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.9 million, a 72.5% increase, with the full-year FY2024 number at $14.0 million, up 33.79% from a year prior.
  • Interest & Investment Income was $3.8 million for Q3 2025 at Centessa Pharmaceuticals, down from $4.4 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.9 million in Q1 2025 to a low of -$1.8 million in Q3 2022.
  • A 4-year average of $2.6 million and a median of $2.9 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: surged 8136.0% in 2023, then grew 2.37% in 2024.
  • Centessa Pharmaceuticals' Interest & Investment Income stood at $39000.0 in 2022, then soared by 7420.51% to $2.9 million in 2023, then surged by 65.19% to $4.8 million in 2024, then fell by 22.29% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Interest & Investment Income are $3.8 million (Q3 2025), $4.4 million (Q2 2025), and $7.9 million (Q1 2025).